PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial

PharmAla Biotech Holdings Inc. (OTC:MDXXF) has announced that it will supply its Good Manufacturing Practice LaNeo MDMA for a clinical trial at Mt. Sinai Health System. The biotechnology company specializes in the research, development, and production of MDMA and novel MDXX-class molecules.

“We’re looking forward to supporting the team at Mt. Sinai …

Full story available on Benzinga.com